Mesothelioma
Also known as: Malignant mesothelioma, Metastasis, Metastases, Metastatic, Mets
Methodology & AI Transparency ⓘ
Mesothelioma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The tissue that lines your lungs, stomach, heart, and other organs is called mesothelium.
- 2 Real-world patient consensus: Mapped to Asthma, COPD & Respiratory Disease under ICD-10-CM C45.9 for Mesothelioma clinical workups.
- 3 Typical cash cost range: Workup highlights for Mesothelioma (C45.9): high-resolution chest imaging in Mesothelioma (C45.9: when indicated).
- 4 Top reported side effects / signs: Key Lungs & Asthma biomarkers for Mesothelioma (C45.9): Resting Pulse Oximetry in Mesothelioma (C45.9: (SpO2)) & Blood Eosinophil Count [Mesothelioma C45.9] (< 150 cells/uL (phenotyping marker) (C45.9)).
Ask our AI Specialists anything about Mesothelioma
What Is Mesothelioma?
The tissue that lines your lungs, stomach, heart, and other organs is called mesothelium. Mesothelioma, also known as malignant mesothelioma, is cancer of that tissue. It usually starts in the lungs, but can also start in the abdomen or other organs. Malignant mesothelioma is rare but serious. Most people who get it have worked or lived in places where they inhaled or swallowed asbestos particles. After being exposed to asbestos, it usually takes a long time for the disease to form.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Mesothelioma (C45.9, Lungs & Asthma) reflects bronchial smooth-muscle hyperresponsiveness [Mesothelioma C45.9]. Cross-referenced with NIH MeSH (Mesothelioma), longitudinal control is benchmarked via Resting Pulse Oximetry in Mesothelioma (C45.9: (SpO2)).
Common Symptoms & Clinical Signs
- • Pain under the rib cage
- • Pain, swelling, or lumps in the abdomen
- • Presentation of Mesothelioma (C45.9): prolonged recovery from in Mesothelioma (C45.9: viral respiratory infections)
- • Secondary Mesothelioma clinical sign: declining stair-climbing stamina in Mesothelioma (C45.9: or frequent rescue)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Mesothelioma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C45.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Resting Pulse Oximetry in Mesothelioma (C45.9: (SpO2)) | 96% – 100% (C45.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Mesothelioma C45.9] | < 150 cells/uL (phenotyping marker) (C45.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Mesothelioma (C45.9: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (C45.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mesothelioma
Treatment selection for Mesothelioma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mesothelioma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very This substudy analysis supplements previous findings that revefenacin provides sustained bronchodilation over 24 hours. International journal of chronic obstructive pulmonary disease • 2024-01-15 • Phase III Randomized Trial | N = 47 | 88/100 | PMID 39429809 ↗ |
| Can This Approach Help? Inside the Latest Research on Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe In children (6-11 years) with uncontrolled moderate-to-severe type 2 asthma, dupilumab 200 mg reduced exacerbation rates and improved lung function for up to 2 years and showed safety consistent with the known dupilumab safety... Pediatric pulmonology • 2024-11-15 • Phase III Randomized Trial | N = 158 | 88/100 | PMID 39016623 ↗ |
| Cost-effectiveness analysis of nivolumab vs. Placebo: Which Works Better for Relapsed malignant mesothelioma? From the perspective of the Chinese healthcare system, nivolumab was not as cost-effective as placebo for relapsed malignant mesothelioma. International journal of clinical pharmacy • 2024-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37991664 ↗ |
| New Insights on A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of: What a 256-Participant Study Found A total of 256 patients were enrolled. Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 256 | 87/100 | PMID 41168047 ↗ |
| Can This Approach Help? Inside the Latest Research on A prognostic score for patients with malignant pleural mesothelioma (MPM) The proposed MRS is prognostic of patient outcome and it fine-tunes the prognosis of patients with pre-treated MPM alone or when used with the already established EORTC score. Lung cancer (Amsterdam, Netherlands) • 2022-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35660972 ↗ |
Mesothelioma Patient Community & “People Like Me” Threads
Filter Mesothelioma community threads and patient logs by age, biological sex, dosage, and treatment duration.